Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
The thrombin activatable fibrinolysis inhibitor (TAFI) is a recently described inhibitor of fibrinolysis. Changes in the concentration of plasma TAFI molecules that are present and functional after activation by thrombin-thrombomodulin complex (TAFI activity) during pregnancy have not previously been studied, and we therefore conducted a present prospective study. Plasma TAFI activity was assayed in 15 healthy non-pregnant women and 176 healthy pregnant women at various stages of gestation. TAFI activity was higher in pregnant than in non-pregnant women. TAFI activity seemed to increase progressively until around 20 weeks of gestation, then maintained a moderately elevated level until delivery, and promptly decreased after delivery.
Watanabe
Takashi
T
Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan. twatnabe@jichi.ac.jp
Minakami
Hisanori
H
Sakata
Yoichi
Y
Matsubara
Shigeki
S
Sato
Ikuo
I
Suzuki
Mitsuaki
M
D000328:Adult; D025901:Carboxypeptidase B2 / Q000097:blood*; D005260:Female; D005865:Gestational Age; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies
D025901:Carboxypeptidase B2